Modern view on the place of riociguat in the treatment of pulmonary hypertension

Modern view on the place of riociguat in the treatment of pulmonary hypertension

Show other versions (1)

Current research is aimed at studying the fundamental therapeutic targets and discovering new drugs acting on previously set targets. Until recently, the only therapeutic strategy to influence the molecular pathway of nitric oxide (NO) – soluble guanylate cyclase (sGC) – cyclic guanosine monophospha...

Full description

Bibliographic Details
Main Authors:	Z.S. Valieva, I.N. Taran, T.V. Martynyuk, I.Ye. Chazova
Format:	Article
Language:	Russian
Published:	"Consilium Medicum" Publishing house 2018-04-01
Series:	Терапевтический архив
Subjects:	pulmonary arterial hypertension therapy optimization riociguat
Online Access:	http://ter-arkhiv.ru/en/archive/2018/vol-90-4-2018/sovremennyy-vzglyad-na-mesto-riotsiguata-v-lechenii-legochnoy-gipertenzii_1457/?element

Similar Items

Modern view on the place of riociguat in the treatment of pulmonary hypertension
by: Z S Valieva, et al.
Published: (2018-04-01)

The achievements of the modern specific therapy of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: focus on the stimulator of soluble guanylate cyclase riociguat
by: S. E. Gratsianskaya, et al.
Published: (2020-10-01)

Results of long-term riociguat therapy, including a switching strategy from sildenafil, in patients with pulmonary hypertension of various genesis
by: S. A. Musashaykhova, et al.
Published: (2023-11-01)

Riociguat in children with pulmonary arterial hypertension: The PATENT–CHILD study
by: Humberto García Aguilar, et al.
Published: (2022-07-01)

CLINICAL CASE OF REPLACEMENT OF ENDOTHELIN RECEPTOR ANTAGONIST (BOSENTAN) BY SOLUBLE GUANYLATE CYCLASE STIMULATOR (RIOCIGUAT) IN THE PATIENT WITH PULMONARY ARTERIAL HYPERTENSION
by: E. A. Devetyarova, et al.
Published: (2018-06-01)

Features of clinical, functional and hemodynamics profile, medical treatment and prognosis evaluation in patients with inoperable chronic thromboembolic pulmonary hypertension and idiopathic pulmonary arterial hypertension according to the Russian registry
by: I E Chazova, et al.
Published: (2019-09-01)

Evaluating Riociguat in the Treatment of Pulmonary Arterial Hypertension: A Real-World Perspective
by: Mihalek AD, et al.
Published: (2022-10-01)

Possibilities of long-term effective treatment of idiopathic pulmonary arterial hypertension by replacing sildenafil with riociguat and using sequential combination therapy: case report
by: S. A. Musashaykhova, et al.
Published: (2022-12-01)

Riociguat: an upcoming therapy in chronic thromboembolic pulmonary hypertension?
by: N. H. Kim
Published: (2010-03-01)

Riociguat: a soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension
by: Lian TY, et al.
Published: (2017-04-01)

THE ROLE OF RIOCIGUAT IN THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION ASSOCIATED WITH CONNECTIVE TISSUE DISEASE
by: O. Ya. Vasiltseva, et al.
Published: (2019-12-01)

Riociguat in patients with chronic thromboembolic pulmonary hypertension: results from an early access study
by: Vallerie V. McLaughlin, et al.
Published: (2017-12-01)

Riociguat is a novel medication for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
by: N. A. Tsareva, et al.
Published: (2016-12-01)

Better efficacy of sequential combination with balloon pulmonary angioplasty after long‐term riociguat for patients with inoperable chronic thromboembolic pulmonary hypertension
by: Wei Wang, et al.
Published: (2024-07-01)

Riociguatas the first innovative guanylatecyclase stimulators class drugs for pulmonary arterial hypertension patients treatment
by: I E Chazova, et al.
Published: (2013-12-01)

Efficacy and safety of riociguat replacing PDE-5is for patients with pulmonary arterial hypertension: A systematic review and meta-analysis
by: Yu-Yang Liu, et al.
Published: (2023-01-01)

Novel use of riociguat in infants with severe pulmonary arterial hypertension unable to wean from inhaled nitric oxide
by: L. T. Domingo, et al.
Published: (2022-12-01)

Switching from sildenafil to riociguat for the treatment of PAH and inoperable CTEPH: Real-life experiences
by: Asger Andersen, et al.
Published: (2017-01-01)

Corrigendum: Efficacy and safety of riociguat replacing PDE-5is for patients with pulmonary arterial hypertension: A systematic review and meta-analysis
by: Yu-Yang Liu, et al.
Published: (2023-02-01)

Meta‐Analysis of Real‐World Clinical Practice to Assess the Effectiveness of Riociguat in Treating Chronic Thromboembolic Pulmonary Hypertension
by: Esra Pamukçu, et al.
Published: (2025-02-01)

Soluble guanylate cyclase stimulation: an emerging option in pulmonary hypertension therapy
by: H. A. Ghofrani, et al.
Published: (2009-03-01)

Modern possibilities of echocardiographic diagnosis in pulmonary arterial hypertension
by: A. A. Klimenko, et al.
Published: (2025-01-01)

Analysis of riociguat and desmethyl riociguat by UPLC-MS/MS and its interaction with quercetin
by: Qingqing Li, et al.
Published: (2024-09-01)

Beneficial effects of riociguat on hemodynamic responses to exercise in CTEPH patients after balloon pulmonary angioplasty – A randomized controlled study
by: Tatsuo Aoki, et al.
Published: (2020-08-01)

Riociguat inhibits ultra‐large VWF string formation on pulmonary artery endothelial cells from chronic thromboembolic pulmonary hypertension patients
by: Takayuki Jujo Sanada, et al.
Published: (2022-10-01)

Experience of the management of patients with pulmonary hypertension in the Republic of Karelia
by: Vadim A Ryabkov, et al.
Published: (2019-09-01)

CARDIOPULMONARY EXCERSISE TESTING IN RISK STRATIFICATION IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION AND CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION
by: I. N. Taran, et al.
Published: (2017-12-01)

New horizons for the use of the second generation of endothelin receptor antagonist macitentan in patients with pulmonary hypertension
by: T.V. Martynyuk, et al.
Published: (2018-04-01)

The impact of riociguat on clinical parameters and quality of life in patients with chronic thromboembolic pulmonary hypertension - results of a retrospective clinical registry
by: Pavel Jansa, et al.
Published: (2021-06-01)

The validation of the questionnaire for the early detection of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
by: Valieva Z.S., et al.
Published: (2016-01-01)

Clinical case of a patient with pulmonary capillary hemangiomatosis: rapid progression or lost time?
by: E. A. Devetyarova, et al.
Published: (2021-11-01)

Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Chronic thromboembolic pulmonary hypertension
by: Eckhard Mayer, et al.
Published: (2014-01-01)

Soluble Guanylate Cyclase Stimulators for Chronic Thromboembolic Pulmonary Hypertension Patients Treatment: New Data
by: M. A. Simakova, et al.
Published: (2020-05-01)

COMPLICATED CLINICAL CASE: CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION IN PATIENT WITH RECIDIVOUS CARDIAC MYXOMA
by: A. M. Zykova, et al.
Published: (2018-03-01)

Treatment Strategy Options in Inoperable Chronic Thromboembolic Pulmonary Hypertension Patients
by: N. V. Marukyan, et al.
Published: (2021-05-01)

EFFICACY OF MULTIDISCIPLINARY MANAGEMENT OF PULMONARY HYPERTENSION
by: I. R. Gaisin, et al.
Published: (2017-02-01)

Possibility of complex medicamental and endovascular treatment of pulmonary hypertension in Takayasu arteritis with predominant pulmonary arteries’ lesion
by: T. V. Маrtynuk, et al.
Published: (2020-06-01)

Advances in Balloon Pulmonary Angioplasty for the Treatment of Chronic Thromboembolic Pulmonary Hypertension
by: GAO Luyang, et al.
Published: (2023-09-01)

Bosentan use in pulmonary arterial hypertension: Russian and foreign experience
by: Z S Valieva, et al.
Published: (2017-08-01)

CASE REPORT ON THE SUCCESSFUL USE OF A NEW SELECTIVE PROSTACYCLIN IP RECEPTOR AGONIST, SELEXIPAG, IN A PATIENT WITH IDIOPATHIC PULMONARY HYPERTENSION
by: Z. S. Valieva, et al.
Published: (2019-12-01)